NAIJA BIZ

Covaxin: COVID-19 vaccine candidate cleared for human trials

 
 
 

In a record feat, India’s Bharat Biotech’s COVID-19 vaccine (Covaxin) has been approved for human trials, making it India’s first domestic candidate to get the green light from the government’s drug regulator as reported by Aljazeera

However, no vaccine has yet been approved for commercial use against the COVID-19 virus, as some COVID-19 vaccines from more than 100 different candidates worldwide are being tested on humans.

The Drug Controller-General of India has approved the Bharat Biotech’s application to conduct a Phase I and II clinical trial of Covaxin, which was developed along with the Indian Council of Medical Research’s National Institute of Virology, the company said in a statement yesterday.

Human clinical trials are scheduled to begin in India next month for the vaccine, which was developed and manufactured in Bharat Biotech’s facility at Genome Valley in Hyderabad, India.

Quick fact about COVID-19; Although for some individuals COVID-19 virus causes only mild illness, but can make other individuals seriously ill. The disease can be very fatal especially among older individuals, and those with compromised immunities (such as diabetes, high blood pressure, or heart problems) appear to be more susceptible.

Bharat Biotech’s COVID-19 vaccine has been approved for human trials, making it India’s first domestic candidate to get the green light from the government’s drug regulator as cases surge in a country with more than 1.3 billion people.

China’s military received the approval to use a COVID-19 vaccine candidate developed by its research unit and CanSino Biologics after clinical trials proved it was safe and showed some efficacy, the company said yesterday. 

Leave a Reply

Your email address will not be published. Required fields are marked *